肿瘤的衰老治疗

doi:10.3760/cma.j.cn371439-20230606-00138

摘要/Abstract

摘要：

肿瘤细胞有衰老反应，衰老的肿瘤细胞具有抑瘤和促瘤的作用。肿瘤的衰老治疗包括诱导肿瘤细胞衰老、清除衰老肿瘤细胞和调节衰老相关表型，但其疗效和不良反应尚需深入研究。检测肿瘤患者肿瘤衰老细胞及其外周血中衰老相关蛋白和代谢物有助于评估衰老治疗的疗效并指导未来的临床试验。

关键词: 肿瘤, 细胞衰老, 治疗

Abstract:

Cancer cells have a senescence response， and senescence in cancer cells have both tumor-suppressive and tumor-promoting effects. Cancer senotherpy includes pro-senescent cancer therapy， senolytic therapy and senomorphic therapy. However， the efficacy and adverse effects need to be thoroughly studied. Detection of senescence-associated proteins and metabolites within the patients' cancer senescent cells and peripheral blood may help to evaluate the efficacy of senotherapy and guide future clinical trials.

Key words: Neoplasms, Cellular senescence, Therapy

岳红云, 张百红. 肿瘤的衰老治疗[J]. 国际肿瘤学杂志, 2023, 50(12): 734-738.

Yue Hongyun, Zhang Baihong. Senotherapies in cancers[J]. Journal of International Oncology, 2023, 50(12): 734-738.

图/表 1

参考文献 49

[1]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. pmid: 35022204
[2]	Di Micco R, Krizhanovsky V, Baker D, et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities[J]. Nat Rev Mol Cell Biol, 2021, 22(2): 75-95. DOI: 10.1038/s41580-020-00314-w.
[3]	He S, Sharpless NE. Senescence in health and disease[J]. Cell, 2017, 169(6): 1000-1011. DOI: 10.1016/j.cell.2017.05.015. pmid: 28575665
[4]	Schmitt CA, Wang B, Demaria M. Senescence and cancer-role and therapeutic opportunities[J]. Nat Rev Clin Oncol, 2022, 19(10): 619-636. DOI: 10.1038/s41571-022-00668-4.
[5]	Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorige-nesis[J]. Nature, 2005, 436(7051): 725-730. DOI: 10.1038/nature03918.
[6]	Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi[J]. Nature, 2005, 436(7051): 720-724. DOI: 10.1038/nature03890.
[7]	Lerma Clavero A, Boqvist PL, Ingelshed K, et al. MDM₂ inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia[J]. Sci Rep, 2023, 13(1): 4583. DOI: 10.1038/s41598-023-31484-0. pmid: 36941277
[8]	Uusküla-Reimand L, Wilson MD. Untangling the roles of TOP2A and TOP2B in transcription and cancer[J]. Sci Adv, 2022, 8(44): eadd4920. DOI: 10.1126/sciadv.add4920.
[9]	Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy[J]. Nat Rev Cancer, 2021, 21(1): 37-50. DOI: 10.1038/s41568-020-00308-y. pmid: 33128031
[10]	Faheem MM, Seligson ND, Ahmad SM, et al. Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives[J]. Cell Death Discov, 2020, 6: 51. DOI: 10.1038/s41420-020-0286-z. pmid: 32566256
[11]	Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy[J]. Science, 2022, 375(6577): eabc1495. DOI: 10.1126/science.abc1495.
[12]	Bousset L, Gil J. Targeting senescence as an anticancer therapy[J]. Mol Oncol, 2022, 16(21): 3855-3880. DOI: 10.1002/1878-0261.13312. pmid: 36065138
[13]	Michalak EM, Burr ML, Bannister AJ, et al. The roles of DNA, RNA and histone methylation in ageing and cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(10): 573-589. DOI: 10.1038/s41580-019-0143-1.
[14]	Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer[J]. Science, 2023, 379(6632): eaaw3835. DOI: 10.1126/science.aaw3835.
[15]	López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of aging: an expanding universe[J]. Cell, 2023, 186(2): 243-278. DOI: 10.1016/j.cell.2022.11.001. pmid: 36599349
[16]	Ruscetti M, Morris JP 4th, Mezzadra R, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer[J]. Cell, 2020, 181(2): 424-441.e21. DOI: 10.1016/j.cell.2020.03.008. pmid: 32234521
[17]	Marin I, Boix O, Garcia-Garijo A, et al. Cellular senescence is immunogenic and promotes antitumor immunity[J]. Cancer Discov, 2023, 13(2): 410-431. DOI: 10.1158/2159-8290.CD-22-0523.
[18]	Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging[J]. Cell, 2017, 169(1): 132-147.e16. DOI: 10.1016/j.cell.2017.02.031. pmid: 28340339
[19]	Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer[J]. Nat Rev Cancer, 2022, 22(6): 340-355. DOI: 10.1038/s41568-022-00450-9. pmid: 35241831
[20]	Gasek NS, Kuchel GA, Kirkland JL, et al. Strategies for targeting senescent cells in human disease[J]. Nat Aging, 2021, 1(10): 870-879. DOI: 10.1038/s43587-021-00121-8. pmid: 34841261
[21]	Martin N, Popgeorgiev N, Ichim G, et al. BCL-2 proteins in senescence: beyond a simple target for senolysis?[J]. Nat Rev Mol Cell Biol, 2023, 24(8): 517-518. DOI: 10.1038/s41580-023-00594-y.
[22]	Fan DNY, Schmitt CA. A cFLIP-flop switch for senolysis[J]. Nat Cancer, 2022, 3(11): 1279-1281. DOI: 10.1038/s43018-022-00455-1.
[23]	Troiani M, Colucci M, D'Ambrosio M, et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer[J]. Nat Commun, 2022, 13(1): 2177. DOI: 10.1038/s41467-022-29824-1. pmid: 35449130
[24]	Crunkhorn S. Driving CARs to clear senescent cells[J]. Nat Rev Drug Discov, 2020, 19(8): 509. DOI: 10.1038/d41573-020-00117-w. pmid: 32581354
[25]	Amor C, Feucht J, Leibold J, et al. Senolytic CART cells reverse senescence-associated pathologies[J]. Nature, 2020, 583(7814): 127-132. DOI: 10.1038/s41586-020-2403-9.
[26]	Crunkhorn S. Fighting ageing with immune checkpoint blockade[J]. Nat Rev Drug Discov, 2023, 22(1): 17. DOI: 10.1038/d41573-022-00194-z.
[27]	Cornen S, Vivier E. Chemotherapy and tumor immunity[J]. Science, 2018, 362(6421): 1355-1356. DOI: 10.1126/science.aav7871. pmid: 30573614
[28]	Chaib S, Tchkonia T, Kirkland JL. Cellular senescence and senolytics: the path to the clinic[J]. Nat Med, 2022, 28(8): 1556-1568. DOI: 10.1038/s41591-022-01923-y. pmid: 35953721
[29]	Wagner V, Gil J. Senescence as a therapeutically relevant response to CDK4/6 inhibitors[J]. Oncogene, 2020, 39(29): 5165-5176. DOI: 10.1038/s41388-020-1354-9. pmid: 32541838
[30]	Xu Y, Kim JS, Li M. Illuminating anti-ageing[J]. Nat Chem, 2023, 15(4): 451-452. DOI: 10.1038/s41557-023-01164-7.
[31]	Dolgin E. Send in the senolytics[J]. Nat Biotechnol, 2020, 38(12): 1371-1377. DOI: 10.1038/s41587-020-00750-1. pmid: 33184478
[32]	Huijbers EJM, Khan KA, Kerbel RS, et al. Tumors resurrect an embryonic vascular program to escape immunity[J]. Sci Immunol, 2022, 7(67): eabm6388. DOI: 10.1126/sciimmunol.abm6388.
[33]	Prieto LI, Sturmlechner I, Goronzy JJ, et al. Senescent cells as thermostats of antitumor immunity[J]. Sci Transl Med, 2023, 15(699): eadg7291. DOI: 10.1126/scitranslmed.adg7291.
[34]	Wang TW, Johmura Y, Suzuki N, et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes[J]. Nature, 2022, 611(7935): 358-364. DOI: 10.1038/s41586-022-05388-4.
[35]	Miyata K, Zhou X, Nishio M, et al. Chromatin conformational changes at human satellite Ⅱ contribute to the senescence phenotype in the tumor microenvironment[J]. Proc Natl Acad Sci U S A, 2023, 120(32): e2305046120. DOI: 10.1073/pnas.2305046120.
[36]	Herranz N, Gallage S, Mellone M, et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype[J]. Nat Cell Biol, 2015, 17(9): 1205-1217. DOI: 10.1038/ncb3225. pmid: 26280535
[37]	Hua Y, Zheng Y, Yao Y, et al. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing[J]. J Transl Med, 2023, 21(1): 403. DOI: 10.1186/s12967-023-04263-8. pmid: 37344841
[38]	van Vliet T, Varela-Eirin M, Wang B, et al. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression[J]. Mol Cell, 2021, 81(9): 2041-2052.e6. DOI: 10.1016/j.molcel.2021.03.018. pmid: 33823141
[39]	Xu M, Tchkonia T, Ding H, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age[J]. Proc Natl Acad Sci U S A, 2015, 112(46): E6301-E6310. DOI: 10.1073/pnas.1515386112.
[40]	Rossi JF, Chiang HC, Lu ZY, et al. Optimisation of anti-interleukin-6 therapy: precision medicine through mathematical modelling[J]. Front Immunol, 2022, 13: 919489. DOI: 10.3389/fimmu.2022.919489.
[41]	Lythgoe MP, Prasad V. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology[J]. Br J Cancer, 2022, 127(5): 785-787. DOI: 10.1038/s41416-022-01893-5.
[42]	Cohen HJ. The cancer aging interface: a research agenda[J]. J Clin Oncol, 2007, 25(14): 1945-1948. DOI: 10.1200/JCO.2007.10.6807. pmid: 17488995
[43]	Minteer CJ, Thrush K, Gonzalez J, et al. More than bad luck: cancer and aging are linked to replication-driven changes to the epigenome[J]. Sci Adv, 2023, 9(29): eadf4163. DOI: 10.1126/sciadv.adf4163.
[44]	Prieto LI, Sturmlechner I, Graves SI, et al. Senescent alveolar macrophages promote early-stage lung tumorigenesis[J]. Cancer Cell, 2023, 41(7): 1261-1275.e6. DOI: 10.1016/j.ccell.2023.05.006. pmid: 37267954
[45]	Walters H. Senescent macrophages drive lung cancer and accumulate in aging[J]. Nat Aging, 2023, 3(7): 757. DOI: 10.1038/s43587-023-00459-1. pmid: 37414988
[46]	Drapela S, Gomes AP. The aging lung reawakens dormant tumor cells[J]. Nat Cancer, 2023, 4(4): 442-443. DOI: 10.1038/s43018-023-00537-8.
[47]	Wong F, Omori S, Donghia NM, et al. Discovering small-molecule senolytics with deep neural networks[J]. Nat Aging, 2023, 3(6): 734-750. DOI: 10.1038/s43587-023-00415-z. pmid: 37142829
[48]	Smer-Barreto V, Quintanilla A, Elliott RJR, et al. Discovery of senolytics using machine learning[J]. Nat Commun, 2023, 14(1): 3445. DOI: 10.1038/s41467-023-39120-1. pmid: 37301862
[49]	Bordon Y. Combining EZH2 inhibition with senescence induction helps immune cells fight pancreatic cancer[J]. Nat Rev Immunol, 2023, 23(7): 411. DOI: 10.1038/s41577-023-00898-2. pmid: 37277561

药物类别	作用机制	临床前研究应用	临床试验
Bcl-2抑制剂	抑制Bcl-2通路	联合化疗药物应用于乳腺癌和肺癌细胞株及异种移植模型	Ⅰ期^[20,23]
mTOR抑制剂	抑制mTOR通路	分别联合多西他赛和氟尿嘧啶应用于前列腺癌和乳腺癌细胞株及异种移植模型	Ⅰ期^[15]
抗PD-1/PD-L1抗体	T细胞免疫反应	联合化疗或CDK4/6抑制剂应用于实体瘤模型	Ⅱ期^[26]